{
  "id": "56c863385795f9a73e000015",
  "type": "yesno",
  "question": "Is macitentan an ET agonist?",
  "ideal_answer": "No, macitentan is anendothelin receptor antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22862294",
    "http://www.ncbi.nlm.nih.gov/pubmed/23830395",
    "http://www.ncbi.nlm.nih.gov/pubmed/25539851",
    "http://www.ncbi.nlm.nih.gov/pubmed/24797866",
    "http://www.ncbi.nlm.nih.gov/pubmed/23984728",
    "http://www.ncbi.nlm.nih.gov/pubmed/24769543",
    "http://www.ncbi.nlm.nih.gov/pubmed/23900878",
    "http://www.ncbi.nlm.nih.gov/pubmed/23077657",
    "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
    "http://www.ncbi.nlm.nih.gov/pubmed/24297706",
    "http://www.ncbi.nlm.nih.gov/pubmed/25060980",
    "http://www.ncbi.nlm.nih.gov/pubmed/24998329",
    "http://www.ncbi.nlm.nih.gov/pubmed/21403842",
    "http://www.ncbi.nlm.nih.gov/pubmed/25457902",
    "http://www.ncbi.nlm.nih.gov/pubmed/25377471",
    "http://www.ncbi.nlm.nih.gov/pubmed/25226600",
    "http://www.ncbi.nlm.nih.gov/pubmed/25604973",
    "http://www.ncbi.nlm.nih.gov/pubmed/23353592",
    "http://www.ncbi.nlm.nih.gov/pubmed/25131455",
    "http://www.ncbi.nlm.nih.gov/pubmed/25084082",
    "http://www.ncbi.nlm.nih.gov/pubmed/23568224",
    "http://www.ncbi.nlm.nih.gov/pubmed/25012164",
    "http://www.ncbi.nlm.nih.gov/pubmed/22348175",
    "http://www.ncbi.nlm.nih.gov/pubmed/22189899",
    "http://www.ncbi.nlm.nih.gov/pubmed/20730702",
    "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
    "http://www.ncbi.nlm.nih.gov/pubmed/24906252",
    "http://www.ncbi.nlm.nih.gov/pubmed/24582812",
    "http://www.ncbi.nlm.nih.gov/pubmed/23997048"
  ],
  "snippets": [
    {
      "text": "Administration of an ET receptor antagonist, either bosentan or macitentan, markedly attenuated PD-induced MMT, fibrosis, angiogenesis, and peritoneal functional decline. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012164",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macitentan is an oral, once-daily, dual endothelin (ET)A and ETB receptor antagonist with high affinity and sustained receptor binding that was approved in the USA, Europe, Canada, and Switzerland for the treatment of PAH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25604973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macitentan (Opsumit\u00ae) is a novel dual endothelin receptor antagonist (ERA) with sustained receptor binding properties developed by Actelion Pharmaceuticals Ltd.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N'-propylaminosulfonamide], is a new dual ET(A)/ET(B) endothelin (ET) receptor antagonist designed for tissue targeting. Selection of macitentan was based on inhibitory potency on both ET receptors and optimization of physicochemical properties to achieve high affinity for lipophilic milieu. In vivo, macitentan is metabolized into a major and pharmacologically active metabolite, ACT-132577. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ET(A) and ET(B) receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory constants within the nanomolar range. In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ET(A) receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ET(B) receptors). In rats with pulmonary hypertension, macitentan prevented both the increase of pulmonary pressure and the right ventricle hypertrophy, and it markedly improved survival. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats. This profile makes macitentan a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18780830",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here we investigated the effects of macitentan, an orally-active, tissue-targeting dual ET receptor antagonist on chronic complications in type 2 diabetes.MAIN METHODS: db/db mice and their age- and sex-matched controls were examined after 2 and 4 months of diabetes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macitentan is a novel dual ETA/ETB receptor antagonist with enhanced tissue distribution and sustained receptor binding properties designed to achieve a more efficacious ET receptor blockade. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24582812",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently oral prostacyclin receptor agonists have shown encouraging results. Many clinical studies targeting the vasoconstrictor ET-1 pathway with receptor antagonists like bosentan and ambrisentan have shown strong results, even more optimism coming from macitentan, the newest drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23997048",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065128",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065131",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065130"
  ],
  "exact_answer": "Yes"
}